Table 4.
Severity scoring of CXR in pediatric patients with COVID-19
| Variable (n, %) | Total N = 106 | Severity score of abnormal CXR findings | p-value | ||
| Mild (n = 81) | Moderate (n = 21) | Severe (n = 4) | |||
| Treatment | |||||
| Favipiravir, n (%) | 34 (32.1%) | 24 (29.6%) | 7 (33.3%) | 3 (75%) | 0.177 |
| Antibiotic, n (%) | 9 (8.5%) | 3 (3.7%) | 3 (14.3%) | 3 (75%) | < 0.001* |
| Steroid, n (%) | 10 (9.4%) | 4 (4.9%) | 3 (14.3%) | 3 (75%) | < 0.001* |
| Remdesivir, n (%) | 9 (8.5%) | 3(3.7%) | 3 (14.3%) | 3 (75%) | < 0.001* |
| Required oxygen support, n (%) | 5 (4.7%) | 1 (1.2%) | 2 (9.5%) | 2 (50%) | 0.002* |
| Cycle threshold of RT-PCR SARS- | |||||
| CoV-2 (n = 22)a | N/A | ||||
| ORF-gene, mean (SD) | 22.6 (6.1) | 23.4 (6.7) | 22.4 (5.3) | 18.8 (5.1) | |
| N-gene, mean (SD) | 21.1 (5.9) | 20.8 (6.7) | 23.1 (4.3) | 16.8 (2.4) | |
| Follow-up CXR (n, %) | Total N = 40 | Severity score of abnormal CXR findings | p-value | ||
| Mild (n = 28) | Moderate (n = 9) | Severe (n = 3) | |||
| Resolution | 25(62.5%) | 17 (60.7%) | 6 (66.7%) | 2 (66.7%) | 1.000 |
| Progression | 6 (15.4%) | 4 (14.3%) | 1 (11.1%) | 1 (33.3%) | 0.387 |
| Stable | 4 (10.3%) | 3 (10.7%) | 1 (11.1%) | 0 (0%) | 1.000 |
| Normal initial CXR findings later became abnormal | 5 (12.8%) | 4 (14.3%) | 1 (11.1%) | 0 (0%) | 1.000 |
CXR Chest radiography, COVID-19 Coronavirus disease-19, N/A Not applicable, RT-PCR, Reverse transcriptase-polymerase chain reaction, ORF Open reading frame, SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2, SD Standard deviation
*Statistical significance p-value ≤ 0.05.
aLarge proportion of missing data in the cycle threshold of RT-PCR SARS-CoV-2 (84 of 106 cases)